Zhengyu Yang

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó et al. · The Lancet Diabetes & Endocrinology · 2022 · 279 citations · Full text

Medicine, Nephrology, Pharmacotherapy +15

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M. Tolaney, Andrew Wardley, Stefania Zambelli et al. · The Lancet Oncology · 2020 · 261 citations

Medicine, Oncology, Pharmacology +16

Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice

Matthew R. Alexander, Christopher W. Moehle, Jason L. Johnson et al. · Journal of Clinical Investigation · 2011 · 218 citations · Full text

Veterinary Medicine, Cardiology, Immunology +14

Global population exposure to landscape fire air pollution from 2000 to 2019

Rongbin Xu, Tingting Ye, Xu Yue et al. · Nature · 2023 · 200 citations · Full text

Public Health, Environmental Sciences, Air Pollution +16